Prognostic value of serial CA 125 measurements during chemotherapy for patients with advanced ovarian cancer by Koper, N.P. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24874
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
IOl!l International Meeting of Gynaecological Oncology 271
carcinoma ol the ovary, which ai ieels younger women. While 60-80% of advanced ovarian cancers will initially respond to cisplatin- 
based chemotherapy, the majority will relapse and acquire a phenotype that renders them resistant to a broad range of drugs. From a 
23 year old patient, small cell carcinoma tissue of the ovary was resected during unilateral adnexectomy, and by the method of  
coilagenase cells were isolated and cultured. These epithelial ovarian tumour cells were found by PCR to express high levels o f  MRP 
and p53 genes. The multi-drug resistance-associated protein plays a significant role in the multi-drug resistance phenotype o f  ovarian 
tumour cel ls.  Furthermore, p53 overexpression is associated with p53 mutations contributing to the dysfunction o f  this 
phosphoprotein such as inhibition of apoptosis after chemotherapy. To circumvent both of these mechanisms o f  drug resistance, we  
entrap cisplatin inside the bilayers of liposomes consisting of 3B[N-(N\ N ’-dimethylaminoethane) carbomoyl], cholesterol and helper 
lipid dioleyol phosphatidyl-ethanolamine, which have been found onto molecules of p53 gene. Entrapped cisplatin is protected by 
binding to plasma proteins and HLD attack. With this approach, cisplatin molecules should overcome MRP efflux, and transfection 
o! p53 could resensitize these cells, including apoptosis. After incubating these tumour cells with the liposomal carriers, we observe 
under electron microscopy a novel mechanism of endocytosis via caveolae, leading to the fusion of liposomes with the nuclear 
envelopes of  the tumour cells. At this point intranuclear restoration of wild type p53 occurs and cisplatin molecules interact with 
nucleophilic sites on DNA, RNA and protein forming bifunctional, intrastrand and cross-links and DNA conformation resulting in 
inhibition of DNA synthesis and apoptosis. Control samples consisting of free wt-p53 and cisplatin incubating with tumour cells have 
not exhibited extensive cellular alterations, implying no cellular entry o f  these substances. Transmission and scanning electron 
microscopy has showed apoptotic changes such as membrane blebbing, chromatin aggregation at the nuclear membrane, cellular 
condensation, formation of membrane bound vesicles such as apoptotic bodies leading to secondary necrosis of the tumour cells 
treated with liposomes. These results were correlated with cytotoxity assays such as measurements o f  metabolic activity by 
telrazolium salt MTT assay, exhibiting reduced metabolic activity and measurement of DNA synthesis by the thymidine analogue 5- 
bromo-2 deosyuridine (BrdU) exhibiting reduced DNA synthesis, implying enhanced chemosensitivity and induction of apoptosis 
compared to tumour cells treated with free wt p53 and cisplatin. Furthermore, measurement of apoptotic frequency by TUNEL (TdT 
mediated dUTP-biotin nick end labeling) exhibited higher apoptotic frequency after liposomal treatment. Finally, flow cytometric 
analysis of  the tumour cells after liposomal treatment has showed cell arrest in G1 phase, while the cells o f  the control samples 
progressed through the cell cycle. Thus, we can observe cytotoxic synergy o f  chemotherapy and gene therapy against ovarian 
carcinoma by circumventing their drug resistance phenotype.
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Aim; Serum CA 125 concentrations measured before and during chemotherapy may provide additional information for prognostic 
assessment of  patients with epithelial ovarian cancer (EOC), and enable discrimination between patients who are likely to benefit from 
further therapy and those who will not.
Materials  and methods;  Medical records of 40 patients with advanced EOC, treated at the Department of Obstetrics and 
Gynaecology of the University Hospital Nijmegen Between July 1984 and April 1993, were examined. All patients had primary 
cytoreductive surgery followed by platinum-based chemotherapy. Serum samples were obtained before surgery and during 
chemotherapy. Follow-up information and patient and tumor characteristics were abstracted from medical records until December I, 
1994. By using multivariate Cox proportional hazards models for disease-free and overall survival it was evaluated whether outcome
prediction was improved by inclusion of serum CA 125 quantitations.
Results; Only F1GO stage and extent of  residual tumor were significant independent prognostic factors before the start o f  
chemotherapy. When such regression models were constructed after subsequent courses of chemotherapy, serum CA 125 
measurements conducted after each ol' the first three chemotherapy courses improved the prediction o f  disease-free survival. 
Prediction of overall survival was improved by inclusion of serum CA 125 measurements after courses 1-6.
Conclusion: Inclusion of serum CA 125 measurements during chemotherapy improved prognostic assessment o f  patients with
advanced ovarian cancer.
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This study was carried out to test the utility of TPS in ovarian cancer. We also intended to evaluate its additional information about 
cell proliferative activity in ovarian tumoral process. 
The study included 63 cases of ovarian pathology (36 malignant and 27 benign). 
The histological and staging composition of malignant group was: 32 epithelial and 4 non-epithelial. F1GO - classification: I = 9 
cases; II = 8; III = 15; IV = 4.
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